about
Screening for mismatch repair deficiency in colorectal cancer: data from three academic medical centers.Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls.Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT studyAn analysis of the association between prostate cancer risk loci, PSA levels, disease aggressiveness and disease-specific mortalityWilms' tumour in adults: a case report and review of the literature.Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.Second-line management of metastatic colorectal cancer.Young patients with synchronous colorectal liver metastases.Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer.Metastatic colorectal cancer: from improved survival to potential cure.Improving response and outcomes for patients with liver-limited metastatic colorectal cancer.Genome-wide association studies of cancer: principles and potential utility.Genitourinary cancer predisposition syndromes.Clinical correlation and molecular evaluation confirm that the MLH1 p.Arg182Gly (c.544A>G) mutation is pathogenic and causes Lynch syndrome.Prostate cancer: germline prediction for a commonly variable malignancy.Multivariate analysis of MLH1 c.1664T>C (p.Leu555Pro) mismatch repair gene variant demonstrates its pathogenicity.Genetic testing and interpretive complexity: a BRCA1 gene mutation example.An overview of triple negative breast cancer for surgical oncologists.Recurrent large genomic rearrangements in BRCA1 and BRCA2 in an Irish case series.Next generation sequencing is informing phenotype: a TP53 example.MUTYH-Associated Polyposis: The Irish Experience>.Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications.Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity.A qualitative analysis of the attitudes of Irish patients towards participation in genetic-based research.Susceptibility loci associated with prostate cancer progression and mortality.False elevation of human chorionic gonadotropin in a patient with testicular cancer.Phase II study of sunitinib in patients with metastatic urothelial cancer.Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma.Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host.Elevated carcinoembryonic antigen and sarcoidosis masquerading as metastatic colon cancer.Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis.Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of response.Diagnosing Lynch Syndrome.Detection of circulating tumor cells in patients with urothelial cancerResponse to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastasesTreatment of patients with colorectal cancer: emphasis on liver metastasesColorectal hepatic metastases: adjuvant chemotherapy and survivalBladder cancer
P50
Q33775296-A7160E75-5347-42C4-AEE7-68B1B2C4019BQ33844055-D05AD6F1-026E-494D-9E66-967F88358189Q33927384-159782B4-8F8F-47C1-A1A7-2AE7D671A645Q36286694-DCE1676E-ACDE-4A18-BE1A-037E4A8ECF44Q36938098-5358D67B-9517-4C9E-8561-57100DF19334Q37019841-A2F851DB-7DF1-41EC-AD17-3CB31CCCD6A7Q37086219-D14CF4AF-E2D7-40C6-A1E4-FFBBB5304E3DQ37445913-DD25A64B-E8C5-4A92-993B-26EB4D0F2EBDQ37677557-AA1AB420-DF73-4C62-88BD-0B92ED1AD6B0Q37762682-FB3AD31A-CF0C-4D6F-811A-FFC45B3F422AQ37772689-E652C5B2-E5F8-475D-A8AE-5DE9F6C20612Q37776479-D5CE5F64-6D79-4A49-908A-FF1E706C8170Q37785238-4CDCDDD1-C25B-44A1-A093-F4E1B5D591F3Q38024724-3A64A569-825B-475E-B1E7-5B4FFDAFF501Q38043095-BB423F21-73F3-4328-A213-EBC0E0974C85Q38109835-8CB5C572-67BD-4369-B3B3-B3C6495584A8Q38287414-30EA766A-F0C5-450A-8D01-5A191089ADF8Q38532757-C54FA5C2-9F81-4FCA-A8A8-7F3517C1A8B5Q38735753-9683FD83-69E5-4355-9E2F-4A505AF1AD41Q38783154-3081A7A8-46BB-4920-AD0B-F5C8F64A0DADQ39394314-A3454650-8A7B-40BC-BF07-41AAA292735DQ39667883-3EC5C041-9822-4FA6-8CC1-5348DF37F868Q39816174-8F1EAFB7-97CB-496D-A76A-D39E91A486E6Q40394578-76EE2D61-C072-4F33-8C34-3EA1DD876BD5Q41785590-0B7E5560-91D2-4FF5-964B-887C702DA6CDQ43103591-2772704A-085F-4FB2-92B0-FF574FA4C321Q43168171-DDC526C2-2422-44B8-B369-7C6712CBDDFEQ43294213-621FFC90-D427-4FA3-AE94-8B39993D2112Q43879300-F584F964-1C77-43CA-90CA-EC93099675ABQ45919635-191DAC46-FDB9-46B8-A56D-0E20522FACAAQ46930577-5F4FCEB3-0BFE-4084-B11C-93D6AB862681Q53696508-D23EE342-DCE6-4054-B8A7-EB1884C67A43Q53708858-58580536-9813-430B-82C3-5B5C0EDDDBFDQ82210837-E8E02550-6F80-4B0E-8B46-4D8666A4EB20Q83367126-8D452D17-E165-4BA0-9B86-0C11E44F194EQ83390197-56931E4D-5B4B-4A82-BECF-D28029440DB5Q84022670-CAA6814C-C3C0-4AFC-A4B8-A68FA2717465Q84578097-1F1137C5-FB85-4974-9D1E-F8C6D43C617A
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
David J Gallagher
@ast
David J Gallagher
@en
David J Gallagher
@es
David J Gallagher
@sl
type
label
David J Gallagher
@ast
David J Gallagher
@en
David J Gallagher
@es
David J Gallagher
@sl
prefLabel
David J Gallagher
@ast
David J Gallagher
@en
David J Gallagher
@es
David J Gallagher
@sl
P106
P21
P31
P496
0000-0002-4468-5991